| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.21 | 2e-09 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.27 | 4e-08 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.19 | 1e-07 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | 0.15 | 4e-07 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.16 | 1e-06 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.17 | 4e-06 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.16 | 6e-06 |
| mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | 0.23 | 1e-05 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.15 | 3e-05 |
| mRNA | AP-24534 | GDSC1000 | pan-cancer | AAC | 0.14 | 5e-05 |